ClinicalTrials.gg
TerminatedNCT00683267Updated May 4, 2009

Efficacy and Safety Study of 4975 in Patients Undergoing Total Hip Replacement

A Phase 2 interventional study of 4975, highly purified capsaicin and Placebo in Arthroplasty, sponsored by Anesiva, Inc.. Terminated at 10 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2009-05-04.

Sponsored by Anesiva, Inc. · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Enrollment of patients has halted prematurely and will not resume. No future patients will be enrolled or treated.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Evaluate the efficacy, safety and tolerability of a single intraoperative dose of 4975 in patients undergoing total hip replacement

Read the detailed description

The purpose of this study is to evaluate the efficacy, safety, and tolerability of a single intraoperative dose of 4975 in patients undergoing primary unilateral total hip arthroplasty

02

Conditions studied

  • Arthroplasty

Keywords

  • THA, Total hip arthroplasty, total hip replacement
03

In context

Lead sponsor

Anesiva, Inc. is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female aged 18 to 85 years with an (ASA) status of I, II, III
  • Planning to undergo unilateral THA
  • In good health and capable of undergoing THA with spinal block and sedation anesthesia
  • No additional planned surgeries during the course of the trial
  • Willing and able to complete the study procedures and pain scales and to communicate meaningfully in English

Key Exclusion Criteria:

  • A greater than 40
  • Known bleeding disorder or is taking agents affecting coagulation preoperatively
  • A medical condition that could adversely impact the patient's participation, safety, or conduct of the study
  • Diabetes mellitus with a known >9.5 or a history of prolonged uncontrolled diabetes
  • Previous hip arthroplasty of the same hip
  • Participated in another clinical trial within 30 days of the planned hip surgery
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
118 participants (actual)

Study arms

  • Experimental
    1

    Study treatment, 4975, is instilled directly into surgical site

    Drug: 4975, highly purified capsaicin

  • Placebo comparator
    2

    Placebo is instilled directly into surgical site

    Drug: Placebo

Interventions

  • Drug4975, highly purified capsaicin

    One dose administered by direct instillation into the surgical site

    Also known as: 4975, Adlea

  • DrugPlacebo

    One dose administered by direct instillation into the surgical site

06

What researchers measure

Primary outcomes

  1. Numerical Rating Scale (NRS) measures of pain at prespecified times

    Time frame: Primary endpoint is 2 days (4-48 hours)

Secondary outcomes

  1. Other efficacy endpoints, safety and tolerability of 4975

    Time frame: 42 Days

07

Study locations

10 sites
  • Alabama Clinical Therapeutics, LLC
    Birmingham, Alabama 35235, United States
  • Lotus Clinical Research, Inc.
    Arcadia, California 91007, United States
  • Glendale Adventist Medical Center
    Glendale, California 91206, United States
  • Webster Orthopaedic Medical Group
    Oakland, California 94612, United States
  • University of California at San Francisco - Mt. Zion
    San Francisco, California 94115, United States
  • Coastal Medical Research, Inc.
    Port Orange, Florida 32127, United States
  • William Beaumont Hospital
    Royal Oak, Michigan 48073, United States
  • William Beaumont Hospital
    Troy, Michigan 48085, United States
  • Sewickley Valley Hospial
    Sewickley, Pennsylvania 15143, United States
  • Covenant Medical Center
    Lubbock, Texas 79410, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Nov 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2008
First posted
May 23, 2008
Start
Sep 2007
Primary completionActual
Nov 2008
CompletionActual
Dec 2008
Last update
May 4, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00683267
Lead sponsor
Anesiva, Inc.
First posted
May 23, 2008
Start date
Sep 2007
Primary completion
Nov 2008
Completion
Dec 2008
Last update
May 4, 2009

Study contacts

Shaun Comfort, MD, MBA
study director · Anesiva, Inc.
William Houghton, MD
study director · Anesiva, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion